Location: | Glasgow |
---|---|
Salary: | £32,868 to £42,717 subject to experience, plus relocation allowance and visa costs if required |
Hours: | Full Time |
Contract Type: | Fixed-Term/Contract |
Placed On: | 14th March 2023 |
---|---|
Closes: | 14th April 2023 |
Mitochondrial Oncogenetics – Dr Payam Gammage (CRUK Beatson Institute)
&
Quantitative Cancer Metabolism Lab – Dr Ed Reznik (Memorial Sloan Kettering Cancer Center)
Investigating the metabolic impact and recurrence of mtDNA mutations in cancer
Salary: from £32,868 to £42,717 subject to experience, plus relocation allowance and visa costs if required.
Contract term: Fixed up to 6 years, subject to successful review at Year 3
About us
The CRUK Beatson Institute where the lab is based is a world leading cancer research institute, situated in the vibrant city of Glasgow in Scotland and hosting approximately 60 postdoctoral researcher scientists at any one time. It has an excellent reputation for fundamental cancer research, including world-class metabolism studies and renowned in vivo modelling of tumour growth and metastasis.
Project outline
The majority of cancers bear mutations of the mitochondrial genome, and while our recent work has identified recurrence and selection of these mutations in tumours (Gorelick et al., 2021, Nature Metabolism) the function of these mutations in tumours is not yet established. In the Mitochondrial Oncogenetics Lab at CRUK BI, we have developed and applied advanced mitochondrial genome engineering techniques to create models of mitochondrial mutant cancer that we study in a variety of contexts.
Together with the Quantitative Cancer Metabolism Lab at Memorial Sloan Kettering Cancer Center, we aim to develop a broad understanding of the impact mtDNA mutations exert within and between tissue lineages, and this project will define the impact of recurrent mtDNA mutations in complex I genes on cancer metabolism and tumour growth across a range of in vitro and in vivo contexts. For a recent review of the field from our labs, see (Kim et al., 2022, Trends in Cancer).
Funded by a jointly held major award from the National Cancer Institute (NIH, USA) to establish a team split between the Gammage and Reznik labs at CRUK BI and MSKCC, this post will be primarily based at CRUK BI but with significant ongoing interaction with the US-based team, including bi-annual meetings in Glasgow and New York.
The successful applicant will be highly enthusiastic, driven to succeed and already have or soon be completing a PhD in mitochondrial or cancer biology and metabolism. Experience of mitochondrial genome engineering, cancer genomics or quantitative approaches to metabolic science are desirable but not essential.
For informal enquiries, please email payam.gammage@glasgow.ac.uk
Equality, Diversity and Inclusion
Our overarching research ethos at the Institute is about excellence, honesty, openness, accountability and integrity. The diversity of our staff and students is also what makes the Institute such a vibrant place to work and advance discoveries in cancer research. Family friendly policies, our collaborative ethos, a focus on good mental health and well-being and opportunities for all help to create an enjoyable and inclusive workplace where your voice matters.
The Institute is also committed to increasing the number of female scientists at the postdoc level and beyond and encourages female applicants to apply. We have recently introduced a highly attractive maternity policy which provides 12-18 months support and funding for postdocs wishing to take time off to spend with their children amongst other family friendly policies
All applications must be made via our website.
Closing Date: 14/4/23 but we may contact promising candidates on a rolling basis, so please apply as soon as you are ready.
Type / Role:
Subject Area(s):
Location(s):